Today, Aldeyra Therapeutics Inc. (ALDX) Lowered by The Zacks Investment Research to Hold

Today, Aldeyra Therapeutics Inc. (ALDX) Lowered by The Zacks Investment Research to Hold
Zacks Investment Research downgraded shares of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) from a buy rating to a hold rating in a research note issued to investors on Monday morning.

According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “

Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating on shares of Aldeyra Therapeutics in a research report on Friday, November 18th. Cowen and Company reaffirmed a buy rating on shares of Aldeyra Therapeutics in a research report on Tuesday, November 15th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Aldeyra Therapeutics has a consensus rating of Buy and an average price target of $14.30.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at 5.95 on Monday. The firm’s market cap is $37.16 million. The firm has a 50-day moving average price of $6.36 and a 200-day moving average price of $6.04. Aldeyra Therapeutics has a 12-month low of $3.39 and a 12-month high of $8.19.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Monday, November 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. Equities research analysts anticipate that Aldeyra Therapeutics will post ($1.76) EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in ALDX. AWM Investment Company Inc. bought a new stake in Aldeyra Therapeutics during the second quarter valued at about $5,222,000. Perceptive Advisors LLC raised its stake in Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock valued at $11,041,000 after buying an additional 700,000 shares during the last quarter. FMR LLC raised its stake in Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock valued at $10,230,000 after buying an additional 360,000 shares during the last quarter. Boxer Capital LLC raised its stake in Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock valued at $1,657,000 after buying an additional 228,084 shares during the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in Aldeyra Therapeutics during the third quarter valued at about $1,110,000. Institutional investors and hedge funds own 50.82% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Related posts

Leave a Comment